Citations to this article
Abstract
A substantial proportion of patients who have recovered from coronavirus disease-2019 (COVID-19) experience COVID-19–related symptoms even months after hospital discharge. We extensively immunologically characterized patients who recovered from COVID-19. In these patients, T cells were exhausted, with increased PD-1+ T cells, as compared with healthy controls. Plasma levels of IL-1β, IL-1RA, and IL-8, among others, were also increased in patients who recovered from COVID-19. This altered immunophenotype was mirrored by a reduced ex vivo T cell response to both nonspecific and specific stimulation, revealing a dysfunctional status of T cells, including a poor response to SARS-CoV-2 antigens. Altered levels of plasma soluble PD-L1, as well as of PD1 promoter methylation and PD1-targeting miR–15-5p, in CD8+ T cells were also observed, suggesting abnormal function of the PD-1/PD-L1 immune checkpoint axis. Notably, ex vivo blockade of PD-1 nearly normalized the aforementioned immunophenotype and restored T cell function, reverting the observed post–COVID-19 immune abnormalities; indeed, we also noted an increased T cell–mediated response to SARS-CoV-2 peptides. Finally, in a neutralization assay, PD-1 blockade did not alter the ability of T cells to neutralize SARS-CoV-2 spike pseudotyped lentivirus infection. Immune checkpoint blockade ameliorates post–COVID-19 immune abnormalities and stimulates an anti–SARS-CoV-2 immune response.
Authors
Cristian Loretelli, Ahmed Abdelsalam, Francesca D’Addio, Moufida Ben Nasr, Emma Assi, Vera Usuelli, Anna Maestroni, Andy Joe Seelam, Elio Ippolito, Stefania Di Maggio, Lara Loreggian, Dejan Radovanovic, Claudia Vanetti, Jun Yang, Basset El Essawy, Antonio Rossi, Ida Pastore, Laura Montefusco, Maria Elena Lunati, Andrea M. Bolla, Mara Biasin, Spinello Antinori, Pierachille Santus, Agostino Riva, Gian Vincenzo Zuccotti, Massimo Galli, Stefano Rusconi, Paolo Fiorina
Citation information
Citations to this article (45)
| Title and authors | Publication | Year |
|---|---|---|
|
Link of TMPRSS2 expression with tumor immunogenicity and response to immune checkpoint inhibitors in cancers
Subbarayan K, Bieber H, Massa C, Rodríguez FA, Hossain SA, Neuder L, Wahbi W, Salo T, Tretbar S, Al-Samadi A, Seliger B |
Journal of Translational Medicine | 2025 |
|
No evidence of immune exhaustion after repeated SARS-CoV-2 vaccination in vulnerable and healthy populations
Benoit JM, Breznik JA, Wu Y, Kennedy A, Liu LM, Cowbrough B, Baker B, Hagerman M, Andary CM, Mushtaha M, Abdalla N, McNicol JD, Gauvreau G, Kim PY, Denburg JA, Costa AP, Leong DP, Nazy I, Duong M, Bramson JL, Larché MJ, Verschoor CP, Bowdish DM |
Nature Communications | 2025 |
|
Anti-PD-L1 therapy altered inflammation but not survival in a lethal murine hepatitis virus-1 pneumonia model
Curran CS, Cui X, Li Y, Jeakle M, Sun J, Demirkale CY, Minkove S, Hoffmann V, Dhamapurkar R, Chumbris S, Bolyard C, Iheanacho A, Eichacker PQ, Torabi-Parizi P |
Frontiers in immunology | 2024 |
|
T Cell Responses in Pregnant Women Who Received mRNA-Based Vaccination to Prevent COVID-19 Revealed Unknown Exposure to the Natural Infection and Numerous SARS-CoV-2-Specific CD4- CD8- Double Negative T Cells and Regulatory T Cells.
Chambers CD, Song J, da Silva Antunes R, Sette A, Franco A |
International journal of molecular sciences | 2024 |
|
Association of interleukin-6, ferritin, and lactate dehydrogenase with venous thromboembolism in COVID-19: a systematic review and meta-analysis
Liu H, Guo N, Zheng Q, Zhang Q, Chen J, Cai Y, Luo Q, Xu Q, Chen X, Yang S, Zhang S |
BMC Infectious Diseases | 2024 |
|
Post-COVID-19 condition: systemic inflammation and low functional exercise capacity.
de Castro GS, Gama LR, Ramos AF, Gatti da Silva G, Teixeira AAS, Cunha-Neto E, de Souza HP, Marie SK, Talib LL, Coelho V, Kalil J, de Araujo AL, Ritto AP, Belon AR, Santos AS, Barrére APN, Sawamura MVY, Lamas CA, Baldi BG, Carvalho CRR, Kulikowski LD, Damiano RF, Imamura M, Rosa Neto JC, Lira FS, Otoch JP, Miguel EC, Battistella L, Forlenza OV, Busatto G, Seelaender M |
Frontiers in Nutrition | 2024 |
|
Persistence of lung structural and functional alterations at one year post‐COVID‐19 is associated with increased serum PD‐L2 levels and altered CD4/CD8 ratio
Buendia\u2010Roldan I, Martínez\u2010Espinosa K, Aguirre M, Aguilar\u2010Duran H, Palma\u2010Lopez A, Palacios Y, Ruiz A, Ramón\u2010Luing LA, Ocaña\u2010Guzmán R, Pérez\u2010Rubio G, Falfán\u2010Valencia R, Selman M, Chavez\u2010Galan L |
Immunity, Inflammation and Disease | 2024 |
|
Immunobiology of COVID-19: Mechanistic and therapeutic insights from animal models
Zheng HY, Song TZ, Zheng YT |
Zoological Research | 2024 |
|
Long COVID science, research and policy.
Al-Aly Z, Davis H, McCorkell L, Soares L, Wulf-Hanson S, Iwasaki A, Topol EJ |
Nature Medicine | 2024 |
|
Evaluation of the safety of PD-1/PD-L1 inhibitors for immunotherapy in patients with malignant tumors after COVID-19 infection: A single-center cohort study.
Liao K, Cheng J, Hu Y, Zhang B, Huang P, Liu J, Zhang W, Hu H, Bai X, Qian Y, Guo D, Ai K, Zhu Y, Huang L |
Cancer medicine | 2024 |
|
PD-L1: From cancer immunotherapy to therapeutic implications in multiple disorders
Lee D, Cho M, Kim E, Seo Y, Cha JH |
Molecular Therapy | 2024 |
|
Altered ACE2 and interferon landscape in the COVID-19 microenvironment correlate with the anti-PD-1 response in solid tumors
Subbarayan K, Al-Samadi A, Schäfer H, Massa C, Salo T, Biehl K, Vaxevanis CK, Ulagappan K, Wahbi W, Reimers M, Drexler F, Moreira-Soto A, Bachmann M, Seliger B |
Cellular and Molecular Life Sciences: CMLS | 2024 |
|
State of Knowledge About Thyroid Cancers in the Era of COVID-19—A Narrative Review
Bronowicka-Szydełko A, Rabczyński M, Dumas I, Fiodorenko-Dumas Ż, Wojtczak B, Kotyra Ł, Kustrzeba-Wójcicka I, Lewandowski Ł, Ponikowska B, Kuzan A, Kluz J, Gamian A, Madziarska K |
Biomedicines | 2024 |
|
SARS-CoV-2 Spike S1 Subunit Triggers Pericyte and Microvascular Dysfunction in Human Pancreatic Islets
Andrade Barboza C, Gonçalves LM, Pereira E, Cruz RD, Andrade Louzada R, Boulina M, Almaça J |
Diabetes | 2024 |
|
Metabolic, genetic and immunological features of relatives of type 1 diabetes patients with elevated insulin resistance
Codazzi V, Salvatore V, Ragogna F, Marzinotto I, Anselmo A, Baldoni N, Pastore MR, Martinenghi S, Stabilini A, Bosi E, Giustina A, Piemonti L, Libman I, Ismail HM, Redondo MJ, Lampasona V, Monti P, Giovenzana A, Petrelli A |
Journal of Endocrinological Investigation | 2024 |
|
Employing T-Cell Memory to Effectively Target SARS-CoV-2
Tun ZH, Htike NT, Kyi-Tha-Thu C, Lee WH |
Pathogens | 2023 |
|
Eruptive halo nevi and new-onset vitiligo post-COVID-19 infection.
Pastukhova E, Ghazawi FM |
JAAD Case Reports | 2023 |
|
Long COVID: Clinical Framing, Biomarkers, and Therapeutic Approaches
Conti V, Corbi G, Sabbatino F, De Pascale D, Sellitto C, Stefanelli B, Bertini N, De Simone M, Liguori L, Di Paola I, De Bernardo M, Tesse A, Rosa N, Pagliano P, Filippelli A |
Journal of Personalized Medicine | 2023 |
|
Impact of COVID-19 Pandemic on Frontline Pembrolizumab-Based Treatment for Advanced Lung Cancer.
Tanvetyanon T, Chen DT, Gray JE |
Journal of Clinical Medicine | 2023 |
|
Pathogen regulatory RNA usage enables chronic infections, T-cell exhaustion and accelerated T-cell exhaustion.
Roe K |
Molecular and Cellular Biochemistry | 2023 |
|
Long COVID: Clinical characteristics, proposed pathogenesis and potential therapeutic targets
Kenny G, Townsend L, Savinelli S, Mallon PW |
Frontiers in Molecular Biosciences | 2023 |
|
COVID-19—The Shift of Homeostasis into Oncopathology or Chronic Fibrosis in Terms of Female Reproductive System Involvement
Petersen E, Chudakova D, Erdyneeva D, Zorigt D, Shabalina E, Gudkov D, Karalkin P, Reshetov I, Mynbaev OA |
International journal of molecular sciences | 2023 |
|
Cognitive impairment in long-COVID and its association with persistent dysregulation in inflammatory markers
Damiano RF, Rocca CC, Serafim AD, Loftis JM, Talib LL, Pan PM, Cunha-Neto E, Kalil J, de Castro GS, Seelaender M, Guedes BF, Nagahashi Marie SK, de Souza HP, Nitrini R, Miguel EC, Busatto G, Forlenza OV |
Frontiers in immunology | 2023 |
|
SARS-CoV-2 vaccination in children and adolescents with and without type 1 diabetes mellitus.
Karavanaki K, Karanasios S, Soldatou A, Tsolia M |
Endocrine | 2023 |
|
A CD64/FcγRI-mediated mechanism hijacks PD-1 from PD-L1/2 interaction and enhances anti-PD-1 functional recovery of exhausted T cells
Joo V, Petrovas C, de Leval L, Noto A, Obeid M, Fenwick C, Pantaleo G |
Frontiers in immunology | 2023 |
|
Immune Response after SARS-CoV-2 Infection with Residual Post-COVID Symptoms
Pongkunakorn T, Manosan T, Surawit A, Ophakas S, Mongkolsucharitkul P, Pumeiam S, Suta S, Pinsawas B, Sookrung N, Saelim N, Mahasongkram K, Prangtaworn P, Tungtrongchitr A, Tangjittipokin W, Mangmee S, Boonnak K, Narkdontri T, Teerawattanapong N, Wanitphadeedecha R, Mayurasakorn K |
Human vaccines | 2023 |
|
Mild to moderate post-COVID-19 alters markers of lymphocyte activation, exhaustion, and immunometabolic responses that can be partially associated by physical activity level— an observational sub-analysis fit- COVID study
Silva BS, Pereira T, Minuzzi LG, Padilha CS, Figueiredo C, Olean-Oliveira T, dos Santos IV, von Ah Morano AE, Marchioto Júnior O, Ribeiro JP, Dos Santos VR, Seelaender M, Teixeira AA, Dos Santos RV, Lemos VD, Freire AP, Dorneles GP, Marmett B, Olean-Oliveira A, Teixeira MF, Seraphim PM, Caseiro A, Pinho RA, Islam H, Little JP, Krüger K, Rosa-Neto JC, Coelho-E-Silva MJ, Lira FS |
Frontiers in immunology | 2023 |
|
Different Prognostic Role of Soluble PD-L1 in the Course of Severe and Non-Severe COVID-19
Sabbatino F, Pagliano P, Sellitto C, Stefanelli B, Corbi G, Manzo V, De Bellis E, Liguori L, Salzano FA, Pepe S, Filippelli A, Conti V |
Journal of Clinical Medicine | 2023 |
|
Targeting PD-1/PD-L1 inhibits rejection in a heterotopic tracheal allograft model of lung transplantation
Kaiho T, Suzuki H, Hata A, Matsumoto H, Tanaka K, Sakairi Y, Motohashi S, Yoshino I |
Frontiers in pharmacology | 2023 |
|
Non-coding RNAs expression in SARS-CoV-2 infection: pathogenesis, clinical significance, and therapeutic targets
Liu X, Xiong W, Ye M, Lu T, Yuan K, Chang S, Han Y, Wang Y, Lu L, Bao Y |
Signal Transduction and Targeted Therapy | 2023 |
|
Th1 cytokine endotype discriminates and predicts severe complications in COVID-19
Takehiro Hasegawa, Takashi Hato, Toshitsugu Okayama, Kazuho Ikeo, Yoshiaki Miyamoto, Niina Iwanaga, Kohjin Suzuki, Maho Yoshida, Kazuto Yamashita, Saya Yamashita, Eiya Tamada, Abdullah Khasawneh, Faith Paran, Rieko Oyama, Toshio Naito, Kenta Noda, Yoko Tabe |
European cytokine network | 2022 |
|
Clinical, radiological, and pathological findings in patients with persistent lung disease following SARS-CoV-2 infection
C Ravaglia, C Doglioni, M Chilosi, S Piciucchi, A Dubini, G Rossi, F Pedica, S Puglisi, L Donati, S Tomassetti, V Poletti |
The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology | 2022 |
|
Inhibitory Immune Checkpoint Receptors and Ligands as Prognostic Biomarkers in COVID-19 Patients
M Al-Mterin, A Alsalman, E Elkord |
Frontiers in immunology | 2022 |
|
COVID-19 immunotherapy: Treatment based on the immune cell-mediated approaches
M Zavvar, A Yahyapoor, H Baghdadi, S Zargaran, S Assadiasl, K Abdolmohammadi, A Abooei, M Sattarian, M JalaliFarahani, N Zarei, A Farahvash, Y Fatahi, G Deniz, M Zarebavani, M Nicknam |
International Immunopharmacology | 2022 |
|
Thyroid Cancer and COVID-19: Prospects for Therapeutic Approaches and Drug Development
N Qu, Z Hui, Z Shen, C Kan, N Hou, X Sun, F Han |
Frontiers in Endocrinology | 2022 |
|
SARS-CoV-2 and cancer: the intriguing and informative cross-talk
Goubran H, Stakiw J, Seghatchian J, Ragab G, Burnouf T |
Transfusion and Apheresis Science | 2022 |
|
Remodeling of T Cell Dynamics During Long COVID Is Dependent on Severity of SARS-CoV-2 Infection
Wiech M, Chroscicki P, Swatler J, Stepnik D, De Biasi S, Hampel M, Brewinska-Olchowik M, Maliszewska A, Sklinda K, Durlik M, Wierzba W, Cossarizza A, Piwocka K |
Frontiers in immunology | 2022 |
|
Role of the PD-1 and PD-L1 axis in COVID-19
R Bonam S, Hu H, Bayry J |
Future Microbiology | 2022 |
|
Should we expect a wave of type 1 diabetes following SARS‐CoV‐2 pandemic?
Montefusco L, Bolla AM, Fiorina P |
Diabetes/Metabolism Research and Reviews | 2022 |
|
Inflammation and vascular dysfunction: The negative synergistic combination of diabetes and COVID‐19
Bolla AM, Loretelli C, Montefusco L, Finzi G, Abdi R, Ben Nasr M, Lunati ME, Pastore I, Bonventre JV, Nebuloni M, Rusconi S, Santus P, Zuccotti G, Galli M, D\u2019Addio F, Fiorina P |
Diabetes/Metabolism Research and Reviews | 2022 |
|
New Insights into SARS-CoV-2 and Cancer Cross-Talk: Does a Novel Oncogenesis Driver Emerge?
Rapti V, Tsaganos T, Vathiotis IA, Syrigos NK, Li P, Poulakou G |
Human vaccines | 2022 |
|
Exhaustion and over-activation of immune cells in COVID-19: Challenges and therapeutic opportunities
Alahdal M, Elkord E |
Clinical Immunology | 2022 |
|
Accelerated T-cell exhaustion: its potential role in autoimmune disease and hyperinflammatory disease pathogenesis
Roe K |
Human Cell | 2022 |
|
COVID-19 associated mold infections: Review of COVID-19 associated pulmonary aspergillosis and mucormycosis.
Huang SF, Ying-Jung Wu A, Shin-Jung Lee S, Huang YS, Lee CY, Yang TL, Wang HW, Chen HJ, Chen YC, Ho TS, Kuo CF, Lin YT |
Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi | 2022 |
|
Persistent T‐cell exhaustion in relation to prolonged pulmonary pathology and death after severe COVID‐19: Results from two Norwegian cohort studies
Trøseid M, Dahl TB, Holter JC, Kildal AB, Murphy SL, Yang K, Quiles\u2010Jiménez A, Heggelund L, Müller KE, Tveita A, Michelsen AE, Bøe S, Holten AR, Hoel H, Mathiessen A, Aaløkken TM, Fevang B, Granerud BK, Tonby K, Henriksen KN, Lerum TV, Müller F, Skjønsberg OH, Barratt\u2010Due A, Dyrhol\u2010Riise AM, Aukrust P, Halvorsen B, Ueland T |
Journal of Internal Medicine | 2022 |
